BRPI1006145A2 - "composição e método para tratamento de diabetes". - Google Patents

"composição e método para tratamento de diabetes".

Info

Publication number
BRPI1006145A2
BRPI1006145A2 BRPI1006145A BRPI1006145A BRPI1006145A2 BR PI1006145 A2 BRPI1006145 A2 BR PI1006145A2 BR PI1006145 A BRPI1006145 A BR PI1006145A BR PI1006145 A BRPI1006145 A BR PI1006145A BR PI1006145 A2 BRPI1006145 A2 BR PI1006145A2
Authority
BR
Brazil
Prior art keywords
composition
treating diabetes
diabetes
treating
Prior art date
Application number
BRPI1006145A
Other languages
English (en)
Inventor
Jerzy Ryszard Szewczyk
Original Assignee
Biokier Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokier Inc filed Critical Biokier Inc
Publication of BRPI1006145A2 publication Critical patent/BRPI1006145A2/pt
Publication of BRPI1006145B1 publication Critical patent/BRPI1006145B1/pt
Publication of BRPI1006145B8 publication Critical patent/BRPI1006145B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI1006145A 2009-01-12 2010-01-11 composição e método para tratamento de diabetes BRPI1006145B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14395109P 2009-01-12 2009-01-12
US61/143,951 2009-01-12
US29377310P 2010-01-11 2010-01-11
PCT/US2010/020629 WO2010081079A2 (en) 2009-01-12 2010-01-11 Composition and method for treatment of diabetes
US61/293,773 2010-01-11

Publications (3)

Publication Number Publication Date
BRPI1006145A2 true BRPI1006145A2 (pt) 2017-05-30
BRPI1006145B1 BRPI1006145B1 (pt) 2021-03-09
BRPI1006145B8 BRPI1006145B8 (pt) 2021-05-25

Family

ID=42317190

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006145A BRPI1006145B8 (pt) 2009-01-12 2010-01-11 composição e método para tratamento de diabetes

Country Status (23)

Country Link
US (2) US8470885B2 (pt)
EP (1) EP2376077B1 (pt)
JP (1) JP5702306B2 (pt)
KR (4) KR20110120866A (pt)
CN (1) CN102355896A (pt)
AU (1) AU2010203413B2 (pt)
BR (1) BRPI1006145B8 (pt)
CA (1) CA2748827C (pt)
CL (1) CL2011001692A1 (pt)
CY (1) CY1119010T1 (pt)
DK (1) DK2376077T3 (pt)
EA (1) EA022631B1 (pt)
ES (1) ES2628233T3 (pt)
HR (1) HRP20170886T1 (pt)
HU (1) HUE034551T2 (pt)
LT (1) LT2376077T (pt)
MX (1) MX2011007393A (pt)
PL (1) PL2376077T3 (pt)
PT (1) PT2376077T (pt)
RS (1) RS56054B1 (pt)
SI (1) SI2376077T1 (pt)
SM (1) SMT201700278T1 (pt)
WO (1) WO2010081079A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
US20220071895A1 (en) * 2009-01-12 2022-03-10 Biokier, Inc. Composition and method for treatment of diabetes
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
WO2012151252A2 (en) * 2011-05-02 2012-11-08 Biokier, Inc. Composition and method for treatment of diabetes
US9144586B2 (en) 2010-04-07 2015-09-29 Incube Labs, Llc Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells
CN103429739B (zh) 2010-05-12 2018-11-13 哥伦比亚大学纽约管理委员会 制备产生和分泌胰岛素的肠内分泌细胞的方法
KR20130055220A (ko) 2011-11-18 2013-05-28 삼성전자주식회사 동박적층판 및 이를 사용한 금속코어기판의 제조방법
PH12020550726B1 (en) * 2011-11-21 2022-11-09 Emmaus Medical Inc Method and compositions for the treatment of diabetes and related symptoms
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
US10487314B2 (en) 2014-06-26 2019-11-26 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
US12551526B2 (en) 2015-04-22 2026-02-17 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
CN107684550B (zh) * 2016-08-03 2020-04-10 徐天宏 糖尿病治疗产品及其制备与应用
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2019165309A1 (en) 2018-02-23 2019-08-29 Ambra Bioscience Llc Compositions and methods for hunger control and weight management
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
JP2022544239A (ja) 2019-08-12 2022-10-17 マサチューセッツ インスティテュート オブ テクノロジー 治療薬の投与のための物品及び方法
US20230190686A1 (en) * 2021-12-17 2023-06-22 Biokier, Inc. Composition and method for treatment of diabetes

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA885473B (en) 1987-08-07 1989-03-29 Century Lab Inc Free fatty acids for treatment of diabetes mellitus
IT1245890B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
JP2001527023A (ja) 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
CA2377301C (en) 1999-06-14 2009-05-12 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US7087579B2 (en) 2001-02-26 2006-08-08 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
US20030203004A1 (en) 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
PT1506963E (pt) 2003-10-28 2005-08-31 Adorkem Technology Spa Processo para a preparacao de citalopram
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
AU2006250354A1 (en) 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
ITMI20052000A1 (it) * 2005-10-21 2007-04-22 Promefarm S R L Compressa gastroresitente a base di butirrato di sodio
CN101404987A (zh) 2006-01-20 2009-04-08 史密丝克莱恩比彻姆公司 磺酰胺衍生物在治疗代射和神经系统疾病中的用途
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
KR101487852B1 (ko) * 2006-12-15 2015-01-29 티마 파운데이션 신규조성물 및 그 용도
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
CA2744697C (en) 2008-11-26 2016-06-21 Satiogen Pharmaceuticals, Inc. Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes
KR101383006B1 (ko) 2009-02-10 2014-04-08 아마린 파마, 인크. 고중성지방혈증 치료 방법
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same

Also Published As

Publication number Publication date
SMT201700278T1 (it) 2017-07-18
PL2376077T3 (pl) 2017-10-31
CN102355896A (zh) 2012-02-15
EP2376077A4 (en) 2012-08-29
US20130102581A1 (en) 2013-04-25
BRPI1006145B8 (pt) 2021-05-25
KR20110120866A (ko) 2011-11-04
US8470885B2 (en) 2013-06-25
US20110275716A1 (en) 2011-11-10
HUE034551T2 (en) 2018-02-28
WO2010081079A3 (en) 2010-11-25
CA2748827C (en) 2017-10-10
KR20170034928A (ko) 2017-03-29
KR20190062609A (ko) 2019-06-05
JP2012515163A (ja) 2012-07-05
AU2010203413B2 (en) 2015-05-14
EA022631B1 (ru) 2016-02-29
DK2376077T3 (en) 2017-06-26
JP5702306B2 (ja) 2015-04-15
MX2011007393A (es) 2011-10-06
PT2376077T (pt) 2017-06-23
CA2748827A1 (en) 2010-07-15
HRP20170886T1 (hr) 2017-09-08
RS56054B1 (sr) 2017-09-29
SI2376077T1 (sl) 2017-09-29
US8680085B2 (en) 2014-03-25
EP2376077B1 (en) 2017-03-15
EP2376077A2 (en) 2011-10-19
BRPI1006145B1 (pt) 2021-03-09
EA201190068A1 (ru) 2012-01-30
ES2628233T3 (es) 2017-08-02
KR20170138573A (ko) 2017-12-15
CL2011001692A1 (es) 2012-04-13
WO2010081079A2 (en) 2010-07-15
AU2010203413A1 (en) 2011-07-14
LT2376077T (lt) 2017-08-10
CY1119010T1 (el) 2018-01-10

Similar Documents

Publication Publication Date Title
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
BRPI0922122A2 (pt) composições e métodos para tratamento de doença celíaca.
BRPI0919575A2 (pt) método, e, composição
BRPI0818732A2 (pt) Composições de análogo de prostaglandina e métodos para tratar condições relacionadas epiteliais.
BRPI0918170A2 (pt) método, e, composição endurecível
BRPI0823277A2 (pt) Composição, e , método
BRPI0809690A2 (pt) Composição de lubrificante, e, método
BRPI0809573A2 (pt) composição, e, método
BR112012000171A2 (pt) composição lubrificante, e, método
BRPI0911757A2 (pt) composiÇÕes e mÉtodos para tratar distérbios digestivos.
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
BRPI0815057A2 (pt) Composto, composição farmacêutica, e, método para tratar infecção.
BRPI0911077A2 (pt) método para tratamento de biomassa
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0814167A2 (pt) Composição, e, método
BR112013003529A2 (pt) "composição aerada, composição de tratamento capilar método para o tratamento capilar"
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI1011012A2 (pt) composição de lubrificante, e, método
BRPI0822472A2 (pt) Método, camundongo, e, composição
BRPI0823238A2 (pt) Composição, e, método
BRPI0719707A2 (pt) Composição e método para dermatite causada por fraldas.
BR112012003151A2 (pt) composição de revestimento, e, método.
BRPI0810738A2 (pt) aparelho e método para tratar materiais com composições.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2862 DE 11-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.